Use of dopamine d3 receptor ligands for the production of drugs for treating renal function disorders
AssigneeAbbVie Deutschland GmbH & Co. KG
InventorsBernd Muhlbauer, Gerhard Gross, Dorothea Starck, Hans-Jorg Treiber
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders.
Claims12
1-10. (canceled)
A method for the treatment of a renal function disorder comprising administering an effective amount of dopamine D3 receptor antagonists to a patient in need thereof, wherein the renal function disorder is selected from the group consisting of
- renal function disorders with glomerular hyperfiltration,
- renal function disorders caused by diabetes mellitus,
- renal function disorders caused by nonrenal hypertension,
- renal function disorders caused by glomerulonephritis,
- renal function disorders caused by ascending urinary tract infections,
- renal function disorders caused by sickle cell anemia,
- renal function disorders caused by compensatory hypertrophy after unilateral nephrectomy, and
- renal function disorders caused by mesangial dysfunction.
A method for the treatment of a renal function disorder associated with glomerular hyperfiltration, albuminurea or glomerular hypertrophy in a patient which comprises administering to said patient an effective amount of a dopamine D3 receptor antagonist.
Dependencies are inferred from the claim text.